Health Care: Drugs

Coherus BioSciences Inc (CHRS: NASDAQ)

$32.7 0.54 | 1.68%
02/26/15 - 04:00 PM ET
Company Income Statement
Dec 2013
Sales 2.75M
Cost of Sales 0.00
Gross Operating Profit 2.75M
Selling, General, and Administrative Expenses 7.46M
Research & Development 31.28M
Operating Income before D & A (EBITDA) -35.99M
Depreciation & Amortization 404.00K
Interest Income 0.00
Other Income - Net -12.35M
Special Income / Charges 0.00
Total Income Before Interest Expenses (EBIT) -48.75M
Interest Expense 5.29M
Pre-Tax Income -54.04M
Income Taxes 0.00
Minority Interest 0.00
Net Income From Continuing Operations -53.64M
Net Income From Discontinued Operations 0.00
Net Income From Total Operations -53.64M
Extraordinary Income/Losses 0.00
Income From Cum. Effect of Acct. Change 0.00
Income From Tax Loss Carryforward 0.00
Other Gains / Losses 0.00
Total Net Income -53.64M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
Preferred Dividends
Net Income Available To Common -53.64M
Basic EPS from Continuing Ops. -2.80
Basic EPS from Discontinued Ops. 0.00
Basic EPS from Total Operations -2.80
Basic EPS from Extraordinary Inc. 0.00
Basic EPS from Cum Effect of Accounting Change 0.00
Basic EPS from Tax Loss Carryf'd. 0.00
Basic EPS from Other Gains (Losses) 0.00
Basic EPS, Total -2.80
Basic Normalized Net Income/Share -2.80
EPS fr Continuing Ops. -2.80
EPS fr Discontinued Ops 0.00
EPS fr Total Ops. -2.80
EPS fr Extraord. Inc. 0.00
EPS fr Cum Effect of Accounting Change 0.00
EPS fr Tax Loss Carfd. 0.00
EPS fr Other Gains (L) 0.00
EPS, Total -2.80
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
Dividends Paid per Share 0.00

Portfolios with CHRS

Latest CHRS Headlines from TheStreet

More Financial News for CHRS

Press Releases for CHRS

See All Press Releases
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter